| 1948 | Riken reorganized into Kagaku-Kenkyusho Launched Penicillin Kaken |
|---|---|
| 1950 | Launched Streptomycin Kaken |
| 1952 | Kagaku-Kenkyusho renamed Kaken Chemicals |
| 1953 | Launched Athletan (anti-trichophyton product) |
| 1962 | Kaken Chemicals listed on the First Section of the Tokyo Stock Exchange |
| 1963 | Completed Shizuoka Factory |
| 1965 | Received the 11th Okochi Memorial Prize |
| 1971 | Received the 17th Okochi Memorial Prize |
| 1982 | Kaken Chemicals merged with Kakenyaku-Kako to form KAKEN PHARMACEUTICAL CO., LTD. |
| 1987 | Launched Artz (anti-osteoarthritis agent) |
| 1988 | Kaken Pharma Co., Ltd. established Launched Adofeed |
| 1989 | Launched Ebrantil (anti-dysuria agent) |
| 1992 | Launched Procylin Launched Mentax |
| 1993 | Launched Artz Dispo (anti-osteoarthritis agent) |
| 1994 | Received the 40th Okochi Memorial Prize |
| 1995 | Received the 41st Okochi Memorial Prize |
| 1996 | Mentax approved by U.S. Food and Drug Administration |
| 1998 | Completed Bunkyo Green Court Launched Seprafilm (post-operative adhesion barrier) |
| 2000 | Won the fiscal 2000 3Rs (Reduce, Reuse and Recycle) Promotion Merit Award and the Minister of Health and Welfare Award |
| 2001 | ISO14001 obtained in Shizuoka site Launched Fiblast Spray (wound-healing agent) |
| 2004 | Launched Mentax Spray |
| 2005 | Obtained the rights to develop, manufacture and sell bFGF globally |
| 2006 | Out-licensed antifungal compound “KP-103” in North America and Europe |
| 2007 | Launched Berasus |
| 2011 | Launched Lipidil |
| 2014 | Launched Clenafin (onychomycosis treatment) |
| 2015 | In-licensed BBI-4000 in Japan and certain other Asian countries |
| 2016 | Acquired exclusive rights to develop and distribute NexoBrid in Japan Out-licensed Clenafin/Jublia in South Korea Launched Regroth dental kit (periodontal regenerative agent) |
| 2017 | Launched collaborative research with Numab Therapeutics AG to develop a new antibody drug Out-licensed Clenafin in Taiwan |
| 2018 | Launched Hernicore (lumbar disc herniation treatment) Out-licensed Clenafin in Hong Kong and Macau |
| 2019 | Acquired exclusive rights to distribute Lenabasum (systemic sclerosis and dermatomyositis treatment) in Japan Out-licensed Clenafin in China Acquired exclusive rights to develop and distribute Ivermectin lotion 0.5% (head lice treatment) in Japan |
| 2020 | Launched Ecclock Gel 5% (primary axillary hyperhidrosis treatment) |
| 2021 | Out-licensed Clenafin in Europe Acquired ARTham Therapeutics Inc. and made it a subsidiary |
| 2023 | Acquired exclusive rights to develop and distribute Seladelpar (Primary biliary cholangitis treatment) in Japan Acquired exclusive rights to develop and distribute Tildacerfont (Congenital adrenal hyperplasia treatment) in Japan |